Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 21 von 24 | SupStack

Metformin – Forschungsarchiv

Studien 1951–2000 von 2110, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

1951RCT2002

Marre M, Howlett H, Lehert P, Allavoine T · Diabet Med (2002)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.

The effect of metformin on hirsutism in polycystic ovary syndrome.

Combination of insulin and metformin in the treatment of type 2 diabetes.

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.

Discontinuation of metformin in type 2 diabetes patients treated with insulin.

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.

Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers.

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect.

Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage)--in healthy human volunteers.

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial.

Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.

Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Improved endothelial function with metformin in type 2 diabetes mellitus.

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.

Beneficial effects of metformin in normoglycemic morbidly obese adolescents.

Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.

Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers.

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food.

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.

Effect of altered gastric emptying and gastrointestinal motility on metformin absorption.

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

Rosiglitazone does not alter the pharmacokinetics of metformin.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.